New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Alto Neuroscience, Inc. (ANRO) vs Omeros Corporation (OMER)

Alto Neuroscience, Inc. and Omeros Corporation are both Biotechnology companies. Alto Neuroscience, Inc. and Omeros Corporation are of similar size ($1.1B and $1.0B). Alto Neuroscience, Inc. has negative trailing earnings, so its P/E is not meaningful; Omeros Corporation trades at 9.5×. Across the 8 metrics below, Omeros Corporation leads on 6 and Alto Neuroscience, Inc. on 2.

Valuation

Metric ANRO OMER Biotechnology median
P/E n/m 9.47 8.49
P/S — 9.23 8.56
P/B 3.99 n/m 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales — 9.59 8.00
Earnings yield (9.60%) 10.56% (35.81%)
Free cash flow yield (6.74%) (3.84%) (25.41%)

Profitability

Metric ANRO OMER Biotechnology median
Gross margin — 97.27% 70.18%
Operating margin — (232.94%) 0.00%
Net margin — (136.61%) 0.00%
Free cash flow margin — (121.65%) 0.00%
Return on equity (46.65%) (63.38%) (51.58%)
Return on assets (40.20%) 45.36% (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ANRO OMER Biotechnology median
Revenue growth (TTM) — (6.29%) 7.20%
EPS growth (last fiscal year) 12.40% 98.15% 29.04%
Revenue growth, 5-year CAGR — 40.44% 9.54%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ANRO OMER Biotechnology median
Debt to equity 0.05 (1.48) 0.00
Current ratio 18.12 2.27 4.79
Net debt to EBITDA 2.40 (0.30) 1.01

Dividend

Metric ANRO OMER Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ANRO OMER Biotechnology median
Market cap 1.06b 1.04b 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack